SCHEMBL1012811

SCHEMBL1012811

COC(=O)c1ccc(CC=CN)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.61
CYP4A11 Q02928 2/20 0.56
CYP4F2 P78329 1/20 0.54
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 2/20 0.49
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA7 P43166 1/20 0.48
TP53 P04637 1/20 0.48
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
TSHR P16473 2/20 0.46
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9133770 0.88 LOXL2 (0.62) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL8180714 0.83 LOXL2 (0.56) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL28224564 0.83 LOXL2 (0.56) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL10638128 0.83 LOXL2 (0.56) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL28744029 0.83 LOXL2 (0.56) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL8180716 0.83 LOXL2 (0.56) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL223801 0.82 LOXL2 (0.63) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL29158562 0.81 LOXL2 (0.54) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL29158561 0.81 LOXL2 (0.54) LOXL2CYP4A11CYP4F2MAPTMEN1
SCHEMBL10587878 0.80 LOXL2 (0.61) LOXL2CYP4A11CYP4F2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735303-B1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMA INC (US) 2011-04-27 EP disclosed
US-7872032-B2 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof AVENTIS PARMACEUTICALS INC. (US) 2011-01-18 US disclosed
US-7638539-B2 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease AVENTIS PHARMACEUTICALS INC. (US) 2009-12-29 US disclosed
US-20090275621-A1 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2009-11-05 US disclosed
US-7576109-B2 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof AVENTIS PHARMACEUTICALS INC. (US) 2009-08-18 US disclosed
EP-1781648-A2 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS Aventis Pharmaceuticals Inc. (US) 2007-05-09 EP disclosed
US-20070099964-A1 1, 3, 4-OXADIAZOL-2-ONES AS PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR DELTA MODULATORS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND METABOLIC DISEASE AVENTIS PHARMACEUTICALS INC. (US) 2007-05-03 US disclosed
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2007-03-15 US disclosed
EP-1735303-A2 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF Aventis Pharmaceuticals, Inc. (US) 2006-12-27 EP disclosed
WO-2005097762-A2 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AVENTIS PHARMACEUTICALS INC. (US) 2005-10-20 WO disclosed
WO-2005097763-A2 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA AVENTIS PHARMACEUTICALS INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275621-A1 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF PPARD, PPARA, PPARG LOXL2 3324/4885CYP4A11 222/4885CYP4F2 773/4885
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF PPARD, PPARA, PPARG LOXL2 3417/4885CYP4A11 225/4885CYP4F2 650/4885
US-20070099964-A1 1, 3, 4-OXADIAZOL-2-ONES AS PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR DELTA MODULATORS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND METABOLIC DISEASE PPARD, PPARA, PPARG LOXL2 2281/4885CYP4A11 474/4885CYP4F2 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.